Dr. Reddy’s Laboratories Ltd ADR (RDY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $12.29B
Last updated: Nov 17, 2026 at 11:05 AM ET
Dr. Reddy’s Laboratories Ltd ADR (RDY) P/E Ratio & Valuation Multiples
Dr. Reddy’s Laboratories Ltd ADR (RDY) trades at 39.6x trailing earnings and 3.5x sales. Its P/S of 3.5x is below its 5-year median of 4.8x. Its forward P/E is 31.6x. The median P/E across 9 similar companies is 18.4x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 25.3% higher over the next year. Its free cash flow yield is 1.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 39.6x |
| Forward P/E | 31.6x |
| Price to sales | 3.5x |
| Price to book | 3.0x |
| EV/EBITDA | 22.2x |
| Price to FCF | 94.2x |
| EV/FCF | 98.9x |
| PEG | 2.0 |
| FCF yield | 1.1% |
Historical Medians
Against its 10-year medians, its P/B is 11.8% below 3.4x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.5x | 4.8x | N/A |
| P/B | 3.0x | 3.5x | 3.4x |
Valuation History
Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 2.6x in 2020 to 7.8x in 2021.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $14.04 | 3.0x | 2.8x |
| 2024 | $15.79 | 3.6x | 3.5x |
| 2023 | $13.92 | 6.8x | 3.6x |
| 2022 | $10.35 | 5.7x | 3.2x |
| 2021 | $13.08 | 7.8x | 316.9x |
| 2020 | $14.26 | 2.6x | 1.0x |
| 2019 | $8.12 | 2.8x | 3.2x |
| 2018 | $7.54 | N/A | N/A |
| 2017 | $7.51 | N/A | 0.6x |
| 2016 | $9.06 | N/A | N/A |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RDY
What is RDY's forward P/E ratio?
Dr. Reddy’s Laboratories Ltd ADR has a forward P/E ratio of 31.6x.
Is RDY stock overvalued?
GNG's valuation label for RDY is Overvalued. Its P/E of 39.6x compares with a median of 18.4x across 9 similar companies.
What is RDY's price to sales ratio?
Dr. Reddy’s Laboratories Ltd ADR has a price to sales ratio of 3.5x.
What is RDY's PEG ratio?
Dr. Reddy’s Laboratories Ltd ADR has a PEG ratio of 2.0.
RDY pages: Overview, Dividends, Financials, Valuation, Competitors